Auckland-based Medtech Global has gained a funding grant of just over $1.6 million (A$1.5 million) to progress with the Australian-based clinical trial of its VitelMed telehealth technology for the remote monitoring of chronic heart failure (CHF) patients.
The Victorian Government’s grant will enable Medtech to take VitelMed to the validation stage of the Health Market Validation Program (Health MVP) in Victoria.
The Health MVP is an A$15 million Victorian Government program to promote innovation in Victoria's healthcare system by encouraging partnership between SMEs and health agenices.
The funding announcement follows the assessment and approval of Medtech’s feasibility study conducted with MEPACS, a service unit of Peninsula Health based in Victoria. Medtech will partner with Peninsula Health to develop a remote monitoring system for CHF patients to automatically report personal health data to their health service via the internet through portable smart devices.
“This will enable CHF patients to remain in their home for longer and reduce periods of hospitalisation,” explains Medtech CEO Vino Ramayah. “It will also enable access to healthcare through teleheath.
“The VitelMed technology solution used for this CHF telehealth will be useful for the management of other chronic diseases in future.”
Rama Kumble, Medtech’s CTO, says the key innovation of the VitelMed cloud-based technology is in enabling clinicians to provide targeted care at the point of need.
“Using commercially-available, popular medical devices, tablets and mobile phones has made our solution affordable and commercially sustainable. The technology enables patients’ involvement in self-care with a simple user interface,” says Kumble.
Medtech's Australian base is located in South Melbourne.